Manchester, United Kingdom - Cytox, a leading developer of assays for risk assessment and prediction of dementia, announced the timing of a presentation discussing the development of a novel proprietary blood-based assay for the assessment of risk of cognitive decline.
The talk, entitled The evaluation of mTOR pathway dysregulation as a novel blood-based phenotypic risk biomarker for the assessment of Alzheimers Disease and dementia will be given on Thursday 17 July, between 08.30 and 10.00am, during the AAIC Symposia and Featured Research Sessions at the Bella Centre, A/S Convention Center, Copenhagen, by Professor Harald Hampel of Université Pierre et Marie Curie (Sorbonne), Paris, France.
More information about the event and Professor Hampels presentation can be found on the AAIC Conference website at http://bit.ly/1q9LzXt.
The presentation refers to two on-going clinical studies in which blood samples are being collected from patients in Europe and in the United States. One study will examine mTOR dysregulation in well-characterized patients who have been diagnosed with probable Alzheimer s Disease, Fronto-temporal Lobe Dementia (FTLD) or Dementia with Lewy bodies (DLB) against cognitively normal control groups.
A second study will evaluate the performance of the assay platform in patients with mild cognitive impairment (MCI) assessing the relationship between the assay output (mTOR dysregulation) and the presence or absence of amyloid plaques in the brain, a pathological hallmark of Alzheimers Disease, using Positron Emission Tomography (PET) imaging.
For more about the mTOR pathway and its potential role in early identification of risk of Dementia and Alzheimers disease, follow this link: www.cytoxgroup.com/information-for-editors